Clinical Trials | Aplastic Anemia and MDS International Foundation

Clinical Trials

Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study.

Prior allogeneic transplant Karnofsky Performance Score < 70% Active central nervous system (CNS) involvement by malignant cells Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progre

Status(es): Recruiting
Study Date(s): Friday, April 1, 2011 to Sunday, October 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 3 months to 30 years
This randomized phase III trial studies caspofungin acetate to see how it works compared to fluconazole in preventing invasive fungal infections in patients with acute myeloid leukemia who are undergoing chemotherapy. Caspofungin acetate or fluconazole may help prevent fungal infections caused by chemotherapy. It is not yet known whether fluconazole is more effective than caspofungin acetate in preventing fungal infections in patients with acute myeloid leukemia who are undergoing chemotherapy.

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Status(es): Recruiting
Study Date(s): Tuesday, September 1, 2009 to Saturday, September 1, 2018
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years to 120 years
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status(es): Recruiting
Study Date(s): Tuesday, September 1, 2015 to Saturday, September 1, 2018
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This phase I/II trial studies the side effects and best dose of 8-chloro-adenosine and how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Drugs used in chemotherapy, such as 8-chloro-adenosine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status(es): Recruiting
Study Date(s): Monday, August 1, 2016 to Friday, March 1, 2019
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
The purpose of this study is to determine the activity of SY-1425 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are positive for a RARA super-enhancer associated biomarker.

A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients

Status(es): Recruiting
Study Date(s): Wednesday, April 1, 2015 to Friday, June 1, 2018
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This multi center randomized (1:1), double blind, placebo controlled Phase 1b/2 study is designed to compare the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of PF 04449913 or placebo when combined with azacitidine in patients with previously untreated Intermediate 2 or High RiskMyelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) with 20-30% blasts and multi lineage dysplasia, and Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a Phase 1b safety lead in and (b) a randomized Phase 2.

A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Status(es): Recruiting
Study Date(s): Wednesday, October 1, 2014 to Saturday, April 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
TEN-010 is a small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of TEN-010 in patients with relapsed/refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractorymyelodysplastic syndrome (MDS). In addition, this trial will assess response to treatment using International Working Group (IWG) response criteria. This study will be conducted in two parts: dose escalation and dose expansion. For dose escalation (Part A), a standard "3+3" design will be used...

A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis

Status(es): Recruiting
Study Date(s): Sunday, June 1, 2014 to Tuesday, November 1, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofribrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH

Status(es): Recruiting
Study Date(s): Thursday, October 1, 2015 to Wednesday, June 1, 2016
Disease(s): paroxysmal nocturnal hemoglobinuria (PNH)
Age Group: 18 years and older
This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.

A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH

Status(es): Recruiting
Study Date(s): Wednesday, October 1, 2014 to Wednesday, June 1, 2016
Disease(s): paroxysmal nocturnal hemoglobinuria (PNH)
Age Group: 18 and older
This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.

A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH

Status(es): Recruiting
Study Date(s): Wednesday, October 1, 2014 to Wednesday, June 1, 2016
Disease(s): paroxysmal nocturnal hemoglobinuria (PNH)
Age Group: 18 years and older
This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.